Gastrointestinal cancers harboring TRK fusions are more susceptible to off-target resistance to TRK inhibition mediated by activation of ERK signaling that may be overcome with MAPK pathway inhibition, while other tumor types are more likely to develop on-target TRK mutations that impair drug binding (Cocco et al. 2019). Here, NTRK1 is linked to neoplasm.